首页> 美国卫生研究院文献>BMC Medicine >Worse prognosis of KRAS c.35 G A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

【2h】

Worse prognosis of KRAS c.35 G A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

机译：KRAS c.35 G的较差预后接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundPrognosis of KRAS wild-type and mutant metastatic colorectal cancer (MCRC) patients (pts) treated with bevacizumab (BEV)-containing chemotherapy is not significantly different. Since specific KRAS mutations confer different aggressive behaviors, the prognostic role of prevalent KRAS mutations was retrospectively evaluated in MCRC pts treated with first line FIr-B/FOx, associating BEV to triplet chemotherapy.

机译：背景接受含贝伐单抗（BEV）化疗的KRAS野生型和突变转移性结直肠癌（MCRC）患者（pts）的预后没有显着差异。由于特定的KRAS突变赋予不同的侵略性行为，因此对一线FIr-B / FOx治疗的MCRC患者（将BEV与三联体化疗相关联）进行回顾性评估了普遍存在的KRAS突变的预后作用。

著录项

期刊名称 BMC Medicine
作者
Gemma Bruera; Katia Cannita; Daniela Di Giacomo; Aude Lamy; Thierry Frébourg; Jean Christophe Sabourin; Mario Tosi; Edoardo Alesse; Corrado Ficorella; Enrico Ricevuto;
展开▼
作者单位

展开▼
年(卷),期 2013(11),-1
年度 2013
页码 59
总页数 10
原文格式 PDF
正文语种
中图分类基础医学;
关键词
KRAS mutation Kras c.35 G A mutation triplet chemotherapy plus bevacizumab metastatic colorectal cancer FIr-B/FOx;

机译：KRAS突变;Kras c.35 G A突变;三联体化疗加贝伐单抗;转移性结直肠癌;FIr-B / FOx;

相似文献

外文文献
中文文献

1. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2013,第1期

机译：KRAS c.35 G的更差预后>接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者
2. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [J] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, BMC Medicine . 2012,第1期

机译：根据转移性疾病的扩展程度，KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值
3. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype [J] . Gemma Bruera, Katia Cannita, Aldo Victor Giordano, International journal of oncology . 2013,第1期

机译：根据二线治疗和KRAS基因型，转移至一线三联体化疗加贝伐单抗，FIr-B / FOx后转移性结直肠癌患者的预后差异
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A Modeling-Based Evaluation of the Evidential Basis for and Cost Effectiveness of Intensive Post-Diagnosis Extra-Colonic Surveillance of Non-Metastatic Colorectal Cancer Patients [D] . Popp, Jonah. 2018

机译：非转移性结直肠癌患者强化诊断后大肠结肠镜检查的证据基础和成本效益的基于模型的评估
6. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease [O] . Gemma Bruera, Katia Cannita, Daniela Di Giacomo, 2012

机译：根据转移性疾病的扩展KRAS基因型在接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的转移性结直肠癌（MCRC）患者中的预后价值
7. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). [O] . Bruera, Gemma, Cannita, Katia, Di Giacomo, Daniela, 2013

机译：KRAS的不良预后c.35 G>接受强化三联化疗加贝伐单抗（FIr-B / FOx）治疗的突变型转移性结直肠癌（MCRC）患者。

Worse prognosis of KRAS c.35 G A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅